Fat lossMetabolicGLP-1

Retatrutide

Triple Agonist (GLP-1/GIP/Glucagon)

Typical Dose

2–12 mg weekly

Route

Injectable

Variants

10mg · 20mg · 30mg · 50mg

Overview

What is Retatrutide?

Retatrutide is a next-generation triple agonist of GLP-1, GIP and glucagon receptors, producing significant fat loss and metabolic improvement in research.

Mechanism of Action

Combined GLP-1 + GIP incretin action with glucagon-driven energy expenditure produces appetite suppression, glycemic control and lipolysis.

Key Benefits

Profound fat loss (>20% in trials)
Improved insulin sensitivity
Increased energy expenditure
Weekly dosing

Research Indications

Obesity researchMost Effective

Type 2 diabetes researchMost Effective

NAFLDEffective

Research Protocols

Disclaimer

These are commonly discussed research protocols and not medical advice. Consult a healthcare provider before use.

Goal	Dose	Frequency	Route
Conservative	2 mg	1x weekly	Subcutaneous
Standard starting dose	4 mg	1x weekly	Subcutaneous
Typical maintenance	8 mg	1x weekly	Subcutaneous
Maximum	12 mg	1x weekly	Subcutaneous

Peptide Interactions

Insulin / sulfonylureas

Hypoglycemia risk

Monitor

AOD-9604

Compatible

Tesamorelin

Compatible

Side Effects & Safety

Common Side Effects

Nausea / vomiting (titrate slowly)
Constipation
Elevated heart rate
Fatigue

Safety Guidelines

For laboratory research use only — not for human consumption
Store reconstituted vials at 2–8°C, use within 30 days
Rotate injection sites to avoid local irritation
Discontinue and consult a clinician if adverse reactions occur

Quality Indicators

≥95% purity verified by HPLC
Third-party tested for sterility
Lyophilized in sealed multi-dose vial
Bacteriostatic water reconstitution
Refrigerated cold-chain shipping

What to Expect

1
Week 1–2
Appetite suppression begins
2
Week 3–6
Steady weight reduction
3
Week 7–12
Visible body composition change
4
Month 3+
Sustained metabolic remodeling

Need a different compound?

Browse all peptides